Literature DB >> 27758882

Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.

Shigeo Ohba1,2, Joydeep Mukherjee2, Tor-Christian Johannessen3, Andrew Mancini2, Tracy T Chow4, Matthew Wood5, Lindsey Jones2, Tali Mazor2, Roxanne E Marshall5, Pavithra Viswanath6, Kyle M Walsh2, Arie Perry2,5, Robert J A Bell2, Joanna J Phillips2,5, Joseph F Costello2, Sabrina M Ronen6, Russell O Pieper7.   

Abstract

Mutations in the isocitrate dehydrogenase gene IDH1 are common in low-grade glioma, where they result in the production of 2-hydroxyglutarate (2HG), disrupted patterns of histone methylation, and gliomagenesis. IDH1 mutations also cosegregate with mutations in the ATRX gene and the TERT promoter, suggesting that IDH mutation may drive the creation or selection of telomere-stabilizing events as part of immortalization/transformation process. To determine whether and how this may occur, we investigated the phenotype of pRb-/p53-deficient human astrocytes engineered with IDH1 wild-type (WT) or R132H-mutant (IDH1mut) genes as they progressed through their lifespan. IDH1mut expression promoted 2HG production and altered histone methylation within 20 population doublings (PD) but had no effect on telomerase expression or telomere length. Accordingly, cells expressing either IDH1WT or IDH1mut entered a telomere-induced crisis at PD 70. In contrast, only IDH1mut cells emerged from crisis, grew indefinitely in culture, and formed colonies in soft agar and tumors in vivo Clonal populations of postcrisis IDH1mut cells displayed shared genetic alterations, but no mutations in ATRX or the TERT promoter were detected. Instead, these cells reactivated telomerase and stabilized their telomeres in association with increased histone lysine methylation (H3K4me3) and c-Myc/Max binding at the TERT promoter. Overall, these results show that although IDH1mut does not create or select for ATRX or TERT promoter mutations, it can indirectly reactivate TERT, and in doing so contribute to astrocytic immortalization and transformation. Cancer Res; 76(22); 6680-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27758882      PMCID: PMC5290072          DOI: 10.1158/0008-5472.CAN-16-0696

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  A genetically tractable model of human glioma formation.

Authors:  J N Rich; C Guo; R E McLendon; D D Bigner; X F Wang; C M Counter
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

Review 2.  The role of telomeres in stem cells and cancer.

Authors:  Cagatay Günes; K Lenhard Rudolph
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

Review 3.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

4.  Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.

Authors:  Y Sonoda; T Ozawa; K D Aldape; D F Deen; M S Berger; R O Pieper
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

Review 5.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

6.  p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.

Authors:  Jenny S L Ho; Weili Ma; Daniel Y L Mao; Samuel Benchimol
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation.

Authors:  Shannon M Lauberth; Takahiro Nakayama; Xiaolin Wu; Andrea L Ferris; Zhanyun Tang; Stephen H Hughes; Robert G Roeder
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

8.  Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.

Authors:  Pedro Castelo-Branco; Sanaa Choufani; Stephen Mack; Denis Gallagher; Cindy Zhang; Tatiana Lipman; Nataliya Zhukova; Erin J Walker; Dianna Martin; Diana Merino; Jonathan D Wasserman; Cynthia Elizabeth; Noa Alon; Libo Zhang; Volker Hovestadt; Marcel Kool; David T W Jones; Gelareh Zadeh; Sidney Croul; Cynthia Hawkins; Johann Hitzler; Jean C Y Wang; Sylvain Baruchel; Peter B Dirks; David Malkin; Stefan Pfister; Michael D Taylor; Rosanna Weksberg; Uri Tabori
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

9.  Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity.

Authors:  Xiang Xu; Jingyue Zhao; Zhen Xu; Baozhen Peng; Qiuhua Huang; Eddy Arnold; Jianping Ding
Journal:  J Biol Chem       Date:  2004-06-01       Impact factor: 5.157

10.  CTCF binds the proximal exonic region of hTERT and inhibits its transcription.

Authors:  Stéphanie Renaud; Dmitri Loukinov; Fred T Bosman; Victor Lobanenkov; Jean Benhattar
Journal:  Nucleic Acids Res       Date:  2005-12-02       Impact factor: 16.971

View more
  24 in total

1.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Authors:  Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

2.  Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer.

Authors:  Georgios Batsios; Céline Taglang; Meryssa Tran; Nicholas Stevers; Carter Barger; Anne Marie Gillespie; Sabrina M Ronen; Joseph F Costello; Pavithra Viswanath
Journal:  Clin Cancer Res       Date:  2022-08-15       Impact factor: 13.801

3.  Commentary: Evaluating potential glioma serum biomarkers, with future applications.

Authors:  Michael Goutnik; Brandon Lucke-Wold
Journal:  World J Clin Oncol       Date:  2022-05-24

4.  Deuterium magnetic resonance spectroscopy enables noninvasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.

Authors:  Céline Taglang; Georgios Batsios; Joydeep Mukherjee; Meryssa Tran; Anne Marie Gillespie; Donghyun Hong; Sabrina M Ronen; Hema Artee Luchman; Russell O Pieper; Pavithra Viswanath
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

5.  Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.

Authors:  Andrew Mancini; Ana Xavier-Magalhães; Wendy S Woods; Kien-Thiet Nguyen; Alexandra M Amen; Josie L Hayes; Christof Fellmann; Michael Gapinske; Andrew M McKinney; Chibo Hong; Lindsey E Jones; Kyle M Walsh; Robert J A Bell; Jennifer A Doudna; Bruno M Costa; Jun S Song; Pablo Perez-Pinera; Joseph F Costello
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

6.  Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.

Authors:  Guo Gord Zhu; Khedoudja Nafa; Narasimhan Agaram; Ahmet Zehir; Ryma Benayed; Justyna Sadowska; Laetitia Borsu; Ciara Kelly; William D Tap; Nicola Fabbri; Edward Athanasian; Patrick J Boland; John H Healey; Michael F Berger; Marc Ladanyi; Meera Hameed
Journal:  Clin Cancer Res       Date:  2019-10-15       Impact factor: 13.801

7.  Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.

Authors:  Pavithra Viswanath; Georgios Batsios; Vinay Ayyappan; Céline Taglang; Anne Marie Gillespie; Peder E Z Larson; H Artee Luchman; Joseph F Costello; Russell O Pieper; Sabrina M Ronen
Journal:  Neuro Oncol       Date:  2021-09-01       Impact factor: 13.029

8.  Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.

Authors:  Daqian Zhan; Ding Ma; Shuang Wei; Bachchu Lal; Yi Fu; Charles Eberhart; John Laterra; Mingyao Ying; Yunqing Li; Alan Meeker; Hernando Lopez-Bertoni; Shuli Xia
Journal:  Mol Cancer Res       Date:  2021-08-04       Impact factor: 5.852

Review 9.  Association between mutant IDHs and tumorigenesis in gliomas.

Authors:  Shigeo Ohba; Yuichi Hirose
Journal:  Med Mol Morphol       Date:  2018-04-09       Impact factor: 2.070

10.  IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.

Authors:  Lili Zhang; Mei Qi; Tingting Feng; Jing Hu; Lin Wang; Xinjun Li; Wei Gao; Hui Liu; Meng Jiao; Zhen Wu; Xinnuo Bai; Yifan Bie; Long Liu; Bo Han
Journal:  Neoplasia       Date:  2018-01-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.